Understanding the problem of digital medication inventory visibility in health systems.

Arlin W Ashemore¹, Antonia Akrap², Lauren Aschermann³, Clayton Irvine⁴, Joshua Foley⁵, John David Scheper⁶, Ryan Tarpey⁷, James G Stevenson⁸

¹Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, and Omnicell Inc., Fort Worth, TX, USA.

²Massachusetts General Hospital, Boston, MA, USA.

³The Ohio State Wexner Medical Center, Columbus, OH, USA.

⁴University of Wisconsin Hospitals and Clinics, Madison, WI, USA.

⁵Omnicell Inc., Fort Worth, TX, USA.

⁶Medical University of South Carolina, Charleston, SC, USA.

⁷The Johns Hopkins Hospital, Baltimore, MD, USA.

⁸University of Michigan College of Pharmacy, Ann Arbor, MI, USA.

PubMed DOI

Abstract

PURPOSE: This project describes and quantifies the perceived degree of digital visibility to medication inventory throughout 6 large health systems. METHODS: In this project, 6 large health systems evaluated their physical medication inventory for digital visibility, or the degree to which physical medication inventory information is viewable in electronic systems, during a 2-year period (2019-20…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.